DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) announces a conference call on Thursday, May 5, 2016 at 4:30 p.m. ET to further update the market on its Manocept™ macrophage targeting programs for immunodiagnostic and immunotherapeutic applications.
